Capstone Therapeutics gets Nasdaq extension to Jan. 4, 2027 to regain $1 minimum bid compliance

Capstone Holding Corp

Capstone Holding Corp

CAPS

0.00
  • Capstone Therapeutics Corporation won a further 180-day Nasdaq grace period to regain compliance with the $1 minimum bid price rule.
  • New deadline set for Jan. 4, 2027; the bid-price threshold is its only remaining listing deficiency.
  • Nasdaq granted the extension after the company met the public float value test, alongside other initial listing requirements.
  • Shareholders authorized a potential reverse stock split of 1-for-5 to 1-for-50 if needed to lift the share price.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607090835BIZWIRE_USPR_____20260709_BW033412) on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.